<DOC>
	<DOC>NCT00152399</DOC>
	<brief_summary>To assess the efficacy and safety of the early administration of somatostatin in infusion during 72 hours plus 2 boluses, compared to placebo in the control of acute severe UGIB with suspicion of PUB.</brief_summary>
	<brief_title>Study to Assess the Efficacy and Safety of Somatostatin in the Treatment of Acute Severe Upper Gastrointestinal Bleeding</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Gastrointestinal Hemorrhage</mesh_term>
	<mesh_term>Peptic Ulcer</mesh_term>
	<mesh_term>Peptic Ulcer Hemorrhage</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Male or female noncirrhotic patients at least 18 years old suspected to bleed from PU. Patients with haematemesis and/or hematochezia and/or melena which have been observed by a member of a clinical team (GP, hospital physician, nurse, ...). Either, documented signs of hypovolemia related to the current bleeding episode Or, occurrence of symptoms of hypovolemia Treatment of the present bleeding episode with somatostatin or its analogues, vasoactive drugs, or endoscopic therapy. Any treatment with PPIs (IV or per os) within the last 48 hours preceding randomisation. Treatment (endotherapy or pharmacotherapy) for upper gastrointestinal ulcer bleeding in the last 30 days. Deficient haemostasis (platelets &lt; 40 x 109/l, international normalised ratio of the prothrombin time &gt; 1.5 (or prothrombin time &lt; 70%), or activated partial thromboplastin time &gt; 40 seconds (or according to the normal ranges validated, from local lab)) Anticoagulant therapy (vitamin K antagonists or heparin including LMW heparins) Terminal stage illness in which endoscopy is contraindicated</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Peptic ulcer bleeding, upper intestinal bleeding, endoscopy, somatostatin</keyword>
</DOC>